Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 110
Filter
1.
BMC Surg ; 21(1): 71, 2021 Feb 02.
Article in English | MEDLINE | ID: mdl-33530973

ABSTRACT

BACKGROUND: Hemobilia due to rupture of hepatic artery pseudoaneurysm and recurrent hemorrhage caused by hepatic artery collateral circulation are both rare complications after liver trauma. There have been a number of separate reports of both complications, but no cases have been reported in which the two events occurred in the same patient. Here we report a recurrent hemorrhage in the bile duct due to hepatic artery pseudoaneurysm secondary to collateral circulation formation after hepatic artery ligation in a patient with liver trauma. CASE PRESENTATION: A 52-year-old male patient was admitted to our hospital for liver trauma (Grade IV according to the American Association for the Surgery of Trauma (AAST) grading system) with active bleeding after a traffic accident. Hepatic artery ligation was performed for hemostasis. Three months after the surgery, the patient was readmitted for melena and subsequent hematemesis. Selective angiography examination revealed the formation of collateral circulation between the superior mesenteric artery and right hepatic artery. Moreover, a ruptured hepatic artery pseudoaneurysm was observed and transcatheter arterial embolization (TAE) was performed for hemostasis at the same time. After the treatment, the patient recovered very well and had an uneventful prognosis until the last follow-up. CONCLUSION: For patients with hepatic trauma, the selection of the site of hepatic artery ligation and the diagnosis and treatment methods of postoperative biliary hemorrhage are crucial for the prognosis of the disease.


Subject(s)
Aneurysm, False , Aneurysm, Ruptured , Hemobilia , Hepatic Artery , Ligation/adverse effects , Liver , Abdominal Injuries/complications , Aneurysm, False/diagnostic imaging , Aneurysm, False/etiology , Aneurysm, False/therapy , Aneurysm, Ruptured/etiology , Aneurysm, Ruptured/therapy , Angiography/methods , Bile Ducts/diagnostic imaging , Bile Ducts/injuries , Collateral Circulation , Embolization, Therapeutic , Hematemesis/etiology , Hematemesis/therapy , Hemobilia/etiology , Hemobilia/therapy , Hepatic Artery/diagnostic imaging , Hepatic Artery/injuries , Hepatic Artery/surgery , Humans , Liver/blood supply , Liver/diagnostic imaging , Liver/injuries , Male , Melena/etiology , Melena/therapy , Middle Aged , Recurrence , Splanchnic Circulation
5.
Eur J Gastroenterol Hepatol ; 32(7): 797-803, 2020 07.
Article in English | MEDLINE | ID: mdl-32175981

ABSTRACT

OBJECTIVES: 'Coffee ground' vomiting (CGV) has classically been considered a sign of upper gastrointestinal bleeding. There is a paucity of data concerning endoscopic findings and outcomes in patients presenting with CGV. The aim of this study was to analyze endoscopic yield and 30-day outcomes in CGV patients. METHODS: Analysis was performed over the period 1992-2005 and four groups were identified: CGV alone, hematemesis alone, melena alone, and hematemesis and melena. Endoscopic yield, requirement for blood transfusion, rebleeding, and mortality rate at 30 days were calculated and compared using logistic regression analysis. RESULTS: 6054 patients (mean age 61.3 years, 3538 male) were included in the study. The hematemesis group was younger compared with the other groups. Therefore, endoscopic yield was adjusted for age and sex. CGV was associated with a significantly lower risk of gastric ulcer, duodenal ulcer, varices, gastric cancer, esophageal cancer, and Mallory-Weiss tears compared with some or all of the other groups. CGV was associated with an increased risk of esophagitis and no source was found. CGV was associated with a lower rate of blood transfusion and rebleeding (all P < 0.0001) but 30-day mortality rates were similar. CGV was less likely to require endoscopic intervention compared with the other groups (all P < 0.001). CONCLUSIONS: CGV is associated with a lower endoscopic yield, requirement for blood transfusion, rebleeding rate, and potential for intervention compared to those with hematemesis, melena or both. Mortality rates are similar suggesting a nonbleeding cause and therefore questions the role of endoscopy in CGV.


Subject(s)
Coffee , Stomach Ulcer , Endoscopy, Gastrointestinal , Gastrointestinal Hemorrhage/diagnosis , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/therapy , Hematemesis/diagnosis , Hematemesis/epidemiology , Hematemesis/etiology , Humans , Male , Melena/epidemiology , Melena/etiology , Melena/therapy , Middle Aged
6.
Eur J Gastroenterol Hepatol ; 31(11): 1334-1341, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31524777

ABSTRACT

OBJECTIVES: Patients with acute upper gastrointestinal bleeding (AUGIB) often manifest as hematemesis and melena. Theoretically, hematemesis will carry worse outcomes of AUGIB. However, there is little real-world evidence. We aimed to compare the outcomes of hematemesis versus no hematemesis as a clinical manifestation of AUGIB at admission in cirrhotic patients. METHODS: All cirrhotic patients with AUGIB who were consecutively admitted to our hospital from January 2010 to June 2014 were considered in this retrospective study. Patients were divided into hematemesis with or without melena and melena alone without hematemesis at admission. A 1:1 propensity score matching analysis was performed. Subgroup analyses were performed based on systemic hemodynamics (stable and unstable) and Child-Pugh class (A and B+C). Sensitivity analyses were conducted in patients with moderate and severe esophageal varices confirmed on endoscopy. Primary outcomes included five-day rebleeding and in-hospital death. RESULTS: Overall, 793 patients were included. Patients with hematemesis at admission had significantly higher five-day rebleeding rate (17.4 versus 10.1%, P = 0.004) and in-hospital mortality (7.9 versus 2.4%, P = 0.001) than those without hematemesis. In the propensity score matching analyses, 358 patients were included with similar Child-Pugh score (P = 0.227) and MELD score (P = 0.881) between the two groups; five-day rebleeding rate (19.0 versus 10.6%, P = 0.026) and in-hospital mortality (8.4 versus 2.8%, P = 0.021) remained significantly higher in patients with hematemesis. In the subgroup and sensitivity analyses, the statistical results were also similar. CONCLUSIONS: Hematemesis at admission indicates worse outcomes of cirrhotic patients with AUGIB, which is useful for the risk stratification of AUGIB.


Subject(s)
Esophageal and Gastric Varices/physiopathology , Hematemesis/physiopathology , Liver Cirrhosis/physiopathology , Melena/physiopathology , Adolescent , Adult , Aged , Aged, 80 and over , Blood Transfusion , Cause of Death , Child , End Stage Liver Disease/mortality , Endoscopy, Gastrointestinal , Esophageal and Gastric Varices/etiology , Female , Gastrointestinal Agents/therapeutic use , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/mortality , Gastrointestinal Hemorrhage/physiopathology , Gastrointestinal Hemorrhage/therapy , Hematemesis/etiology , Hematemesis/therapy , Hepatic Encephalopathy/mortality , Hormones/therapeutic use , Hospital Mortality , Humans , Liver Cirrhosis/complications , Liver Failure/mortality , Male , Melena/etiology , Melena/therapy , Middle Aged , Multiple Organ Failure/mortality , Octreotide/therapeutic use , Proton Pump Inhibitors/therapeutic use , Recurrence , Severity of Illness Index , Somatostatin/therapeutic use , Young Adult
8.
J Dermatol ; 46(1): 73-75, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30474867

ABSTRACT

Generalized pustular psoriasis (GPP) is a systemic inflammatory disease that presents with erythema and sterile pustules, pathologically characterized by Kogoj's spongiform pustules. GPP is sometimes accompanied by mucosal involvement, and the most common lesion is on the tongue. IL36RN mutation was found to contribute to the pathogenesis of GPP especially in patients who develop GPP without a past medical history of psoriasis vulgaris. The association of IL36RN mutation with mucosal involvement in GPP is controversial. We herein report a 60-year-old male GPP patient with no past history of plaque psoriasis presenting with not only severe skin lesions and arthritis but also severe mucosal involvements of pharyngeal and gastrointestinal lesions, which led to gastrointestinal bleeding. Our case did not have any mutation in the IL36RN gene. We should be aware that severe GPP can cause gastrointestinal bleeding. The relevancy of IL36RN mutation with mucosal involvement in GPP remains to be elucidated.


Subject(s)
Dermatologic Agents/therapeutic use , Duodenal Ulcer/etiology , Esophageal Diseases/etiology , Melena/etiology , Psoriasis/complications , Antibodies, Monoclonal, Humanized/therapeutic use , Biopsy , Duodenal Ulcer/diagnostic imaging , Duodenal Ulcer/pathology , Endoscopy, Digestive System , Erythrocyte Transfusion , Esophageal Diseases/diagnostic imaging , Esophageal Diseases/pathology , Esophageal Mucosa/diagnostic imaging , Esophageal Mucosa/pathology , Humans , Interleukins/genetics , Intestinal Mucosa/diagnostic imaging , Intestinal Mucosa/pathology , Male , Melena/diagnostic imaging , Melena/pathology , Melena/therapy , Middle Aged , Mutation , Psoriasis/drug therapy , Psoriasis/genetics , Psoriasis/pathology , Skin/pathology , Treatment Outcome
10.
Am J Gastroenterol ; 113(3): 358-366, 2018 03.
Article in English | MEDLINE | ID: mdl-29380820

ABSTRACT

OBJECTIVES: Numerous reviews indicate bloody hematemesis signifies more severe bleeding than coffee-grounds hematemesis. We assessed severity and outcomes related to bleeding symptoms in a prospective study. METHODS: Consecutive patients presenting with hematemesis or melena were categorized as bloody emesis (N=1209), coffee-grounds emesis without bloody emesis (N=701), or melena without hematemesis (N=1069). We assessed bleeding severity (pulse, blood pressure) and predictors of outcome (hemoglobin, risk stratification scores) at presentation, and outcomes of bleeding episodes. The primary outcome was a composite of transfusion, intervention, or mortality. RESULTS: Bloody and coffee-grounds emesis were similar in pulse ≥100 beats/min (35 vs. 37%), systolic blood pressure ≤100 mm Hg (12 vs. 12%), and hemoglobin ≤100 g/l (25 vs. 27%). Risk stratification scores were lower with bloody emesis. The composite end point was 34.7 vs. 38.2% for bloody vs. coffee-grounds emesis; mortality was 6.6 vs. 9.3%. Hemostatic intervention was more common (19.4 vs. 14.4%) with bloody emesis (due to a higher frequency of varices necessitating endoscopic therapy), as was rebleeding (7.8 vs. 4.5%). Outcomes were worse with hematemesis plus melena vs. isolated hematemesis for bloody (composite: 62.4 vs. 25.6%; hemostatic intervention: 36.5 vs. 13.8%) and coffee-grounds emesis (composite: 59.1 vs. 27.1%; hemostatic intervention: 26.4 vs. 8.1%). CONCLUSIONS: Bloody emesis is not associated with more severe bleeding episodes at presentation or higher mortality than coffee-grounds emesis, but is associated with modestly higher rates of hemostatic intervention and rebleeding. Outcomes with hematemesis are worsened with concurrent melena. The presence of bloody emesis plus melena potentially could be considered in decisions regarding timing of endoscopy.


Subject(s)
Hematemesis/physiopathology , Melena/physiopathology , Upper Gastrointestinal Tract , Aged , Blood Preservation , Blood Transfusion/statistics & numerical data , Esophageal and Gastric Varices/complications , Esophageal and Gastric Varices/surgery , Female , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/mortality , Gastrointestinal Hemorrhage/physiopathology , Gastrointestinal Hemorrhage/therapy , Heart Rate , Hematemesis/etiology , Hematemesis/mortality , Hematemesis/therapy , Hemoglobins/metabolism , Hemostasis, Endoscopic/statistics & numerical data , Humans , Male , Melena/etiology , Melena/mortality , Melena/therapy , Middle Aged , Mortality , Prospective Studies , Recurrence , Risk Assessment , Severity of Illness Index
12.
Gastrointest Endosc ; 86(6): 1028-1037, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28396275

ABSTRACT

BACKGROUND AND AIMS: We performed a prospective multi-national study of patients presenting to the emergency department with upper GI bleeding (UGIB) and assessed the relationship of time to presentation after onset of UGIB symptoms with patient characteristics and outcomes. METHODS: Consecutive patients presenting with overt UGIB (red-blood emesis, coffee-ground emesis, and/or melena) from March 2014 to March 2015 at 6 hospitals were included. Multiple predefined patient characteristics and outcomes were collected. Rapid presentation was defined as ≤6 hours. RESULTS: Among 2944 patients, 1068 (36%) presented within 6 hours and 576 (20%) beyond 48 hours. Significant independent factors associated with presentation ≤6 hours versus >6 hours on logistic regression included melena (odds ratio [OR], 0.22; 95% CI, 0.18-0.28), hemoglobin ≤80 g/L (OR, 0.47; 95% CI, 0.36-0.61), altered mental status (OR, 2.06; 95% CI, 1.55-2.73), albumin ≤30 g/L (OR, 1.43; 95% CI, 1.14-1.78), and red-blood emesis (OR, 1.29; 95% CI, 1.06-1.59). Patients presenting ≤6 hours versus >6 hours required transfusion less often (286 [27%] vs 791 [42%]; difference, -15%; 95% CI, -19% to -12%) because of a smaller proportion with low hemoglobin levels, but were similar with regard to hemostatic intervention (189 [18%] vs 371 [20%]), 30-day mortality (80 [7%] vs 121 [6%]), and hospital days (5.0 ± 0.2 vs 5.0 ± 0.2). CONCLUSIONS: Patients with melena alone delay their presentation to the hospital. A delayed presentation is associated with a decreased hemoglobin level and increases the likelihood of transfusion. Other outcomes are similar with rapid versus delayed presentation. Time to presentation should not be used as an indicator for poor outcome. Patients with delayed presentation should be managed with the same degree of care as those with rapid presentation.


Subject(s)
Duodenal Diseases/blood , Esophageal Diseases/blood , Hematemesis/blood , Melena/blood , Patient Acceptance of Health Care/statistics & numerical data , Stomach Diseases/blood , Aged , Blood Transfusion/statistics & numerical data , Confusion/etiology , Duodenal Diseases/mortality , Duodenal Diseases/therapy , Esophageal Diseases/mortality , Esophageal Diseases/therapy , Female , Glasgow Coma Scale , Hematemesis/mortality , Hematemesis/therapy , Hemoglobins/metabolism , Hemostasis, Endoscopic/statistics & numerical data , Humans , Length of Stay/statistics & numerical data , Lethargy/etiology , Male , Melena/mortality , Melena/therapy , Middle Aged , Prognosis , Prospective Studies , Serum Albumin/metabolism , Stomach Diseases/mortality , Stomach Diseases/therapy , Stupor/etiology , Time-to-Treatment
13.
World J Gastroenterol ; 23(10): 1920-1924, 2017 Mar 14.
Article in English | MEDLINE | ID: mdl-28348499

ABSTRACT

Gastrointestinal stromal tumors (GISTs) represent the most common mesenchymal tumors of the alimentary tract. These tumors may have different clinical and biological behaviors. Malignant forms usually spread via a hematogenous route, and lymph node metastases rarely occur. Herein, we report a patient with a jejunal GIST who developed supraclavicular lymph node metastasis. We conclude that lymphatic diffusion via the mediastinal lymphatic station to the supraclavicular lymph nodes can be a potential metastatic route for GISTs.


Subject(s)
Gastrointestinal Stromal Tumors/complications , Gastrointestinal Stromal Tumors/pathology , Melena/etiology , Stomach Neoplasms/complications , Stomach Neoplasms/pathology , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Biopsy, Needle , Chemotherapy, Adjuvant , Erythrocyte Transfusion , Gastrointestinal Stromal Tumors/diagnosis , Gastrointestinal Stromal Tumors/therapy , Humans , Imatinib Mesylate/administration & dosage , Imatinib Mesylate/therapeutic use , Jejunum/pathology , Jejunum/surgery , Lymph Nodes/pathology , Lymphatic Metastasis , Male , Melena/therapy , Middle Aged , Neck Dissection , Neoplasm Grading , Positron Emission Tomography Computed Tomography , Stomach Neoplasms/diagnosis , Stomach Neoplasms/therapy , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL
...